Current Clinical Trials

The Pulmonary Fibrosis Foundation is pleased to provide links to active investigational research in pulmonary fibrosis. The information is from the National Institutes of Health (NIH); a complete list of active, enrolled, and recently completed clinical trials is available at www.clinicaltrials.gov.

All studies listed below are currently recruiting participants per the clinicaltrials.gov website. Updated March 6, 2014.

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
Sponsor: University of Miami

The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis (Cough-IPF)
Sponsor: Erasmus Medical Center, Netherlands

The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Sponsor: National Institutes of Health Clinical Center (CC)

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Boehringer Ingelheim Pharmaceuticals

Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Sponsor: InterMune

A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Start Date: October 2013
Sponsor: Hoffman-La Roche

A Linkage and Association Study in Pulmonary Fibrosis (GWAS)
Sponsor: National Jewish Health

Pulmonary Fibrosis Contact Registry
Sponsor: National Jewish Health

Supplemental Oxygen in Pulmonary Fibrosis

Start Date: October 9, 2013
Sponsor: National Jewish Health

The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease
Sponsor: Meir Medical Center, Kfar Saba, Israel, 972

Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis (CMM/FPI)
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra, Spain

Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis
Sponsor: Klinikum Berchtesgadener Land der Schön-Kliniken, Bavaria, Germany, 83471

Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis
Sponsor: Gabriela Riemekasten, Berlin, Germany

Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease (Dyspnea_ILD)
Sponsor: University of British Columbia

Participation Program for Pulmonary Fibrosis
Sponsors: The Patient-Centered Outcomes Research Institute, National Jewish Health

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: FibroGen

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Sponsor: Bristol-Myers Squibb
Learn More About the Study

A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Gilead Sciences

STX-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Stromedix, Inc.

Study in Subjects with PAH and PH Secondary to IPF Using Inhaled NITROsyl (PHiano)
Sponsor: Geno LLC

Study of Inhaled Carbon Monoxide to Treat IPF
Sponsor: Brigham and Women's Hospital

A Proof of Mechanism Study with GSK2126458 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: GlaxoSmithKline

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Sanofi

Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: University of Virginia

IPF Drug Deposition Study (Topical-IPF)
Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Evaluation of the Hospital2Home Palliative Care Service for Patients with Advanced Progressive Lung Disease (H2H-ILD)
Sponsor: Royal Marsden NHS Foundation Trust, UK

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis
Sponsor: Medimmune LLC

The Six Minute Walk Test: Influence of Patient Effort on Results and Interpretation (fast vs far)
Sponsor: Inova Health Care Services

Study of Default Options in Advance Directives
Sponsor: Philadelphia Veterans Affairs Medical Center

Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
Sponsor: University of California, San Francisco

Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF) (INSIGHTS-IPF)
Sponsor: Dresden University of Technology

Conducting Airways in Lung Fibrosis (VACFI)
Sponsor: Assistance Publique - Hôpitaux de Paris

A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis
Sponsor: AstraZeneca

A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)
Sponsors:
Royal Brompton & Harefield NHS Foundation Trust
GlaxoSmithKline

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF)
Sponsors:
University of Pittsburgh
National Institutes of Health (NIH)

A Study to Characterize Lung Function, Airway Morphometry, Pharyngometry and Inhalation Profiles From Patients With Idiopathic Pulmonary Fibrosis (IPF)
Sponsors:
GlaxoSmithKline
The University Hospital Antwerp and the University Antwerp

Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis
Sponsors:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Junta de Andalucia

Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study)
Sponsor: GlaxoSmithKline

Nandrolone Decanoate in the Treatment of Telomeropathies - Male Hormones for Telomere Related Diseases
Sponsor: University of Sao Paulo

Clinical Utility of Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases
Sponsor: Singapore General Hospital

The Pennsylvania Idiopathic Pulmonary Fibrosis State-wide Research Registry
Sponsor: University of Pittsburgh

Prospective, Longitudinal Cohort Trial of Patients With Idiopathic Pulmonary Fibrosis (IPF) and Healthy Control Patients. Clinical Data, Blood, and Bronchiolavage (BAL) Fluid Will be Collected Over 12 Months.
Sponsor: University of California, San Francisco

Prospective Evaluation of Patients With Idiopathic Pulmonary Fibrosis Through an IPF Registry
Sponsor: New York University School of Medicine

Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)
Sponsor: University of Nottingham, Medical Research Council, GlaxoSmithKline

Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis
Sponsor: Clay Marsh MD

The Role of Microaspiration in Idiopathic Pulmonary Fibrosis
Sponsor: University of California, San Francisco

Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Search for additional clinical trials at http://www.clinicaltrials.gov/ or https://www.clinicaltrialsregister.eu.